남은미 교수

PURPOSE: When designing this trial, there was no evidence that salvage chemotherapy (SLC) in advanced gastric cancer (AGC) resulted in substantial prolongation of survival when compared with best supportive care (BSC). However, SLC is often offered to pretreated patients with AGC for anecdotal reasons. PATIENTS AND METHODS: Patients with AGC with one or two prior chemotherapy regimens involving both fluoropyrimidines and platinum and with an Eastern Cooperative Oncology Group performance status

The presented multimodal CT evaluation improves detection rate and prediction of the final size of infarction in comparison with unenhanced CT, CT angiography, and perfusion CT alone.

BACKGROUND AND PURPOSE: With new CT technologies, including CT angiography (CTA), perfusion CT (PCT), and multidetector row technique, this method has regained interest for use in acute stroke assessment. We have developed a score system based on Multimodal Stroke Assessment Using CT (MOSAIC), which was evaluated in this prospective study. METHODS: Forty-four acute stroke patients (mean age, 63.8 years) were enrolled within a mean of 3.0+/-1.9 hours after symptom onset. The MOSAIC score (0 to 8

AIMS AND BACKGROUND: The HER2 gene encodes a 185-kd transmembrane glycoprotein receptor (p185(HER2)) that has partial homology with the epidermal growth factor receptor and shares intrinsic tyrosine kinase activity. The phosphatase and tensin homolog mutated on chromosome ten (PTEN) gene product is a protein tyrosine phosphatase that participates in modulating the phosphoinositide 3-kinase pathway which has antagonizing activity to protein tyrosine kinase. The authors investigated the correlatio

OBJECTIVE: To evaluate the efficacy of intravenous lorazepam as premedication for bone marrow aspiration and biopsy (BMAB). DESIGN: Randomized, double-blind, placebo-controlled. PATIENTS: One hundred and thirty-eight consenting patients planned to receive BMAB. INTERVENTION: Patients were randomly assigned to receive either intravenous lorazepam 1 mg or placebo just prior to BMAB. SETTING: Tertiary referral center, inpatient setting. OUTCOME MEASURES: A questionnaire was used to determine the pa

Imatinib mesylate is the first molecule of targeted therapy in chronic myelogenous leukaemia inhibiting constitutively activated BCR-ABL kinase. There are no long-term follow-up studies of large sample sizes to assess the toxicity of the use of imatinib mesylate over 10 years. Several cases of hepatotoxicity, including fatal liver failure, have been associated with the long-term use of imatinib mesylate. We report here on a patient who experienced immediate dominant cholestatic damage of the liv

5567 Background: To compare the diagnostic accuracy of positron emission tomography/computed tomography (PET/CT), Doppler ultrasonography (US), Computed tomography (CT), and magnetic resonance imaging (MRI) for detection of ovarian cancer and to assess the role of PET/CT in evaluating dissemination of ovarian cancer. Methods: One hundred thirty three women suspected to have ovarian cancer were enrolled in a prospective study before surgery between March 2005 and August 2007. The accuracy of each

간 전이를 동반한 대장암 환자에서 일부는 간 절제로 완치를 시도할 수 있으며 20~30%에서 재발 없이 장기생존을 기대할 수 있으나 대부분의 환자가 수술이 불가능하거나 수술 후 재발된다. 최근 표적치료제를 포함한 항암화학요법의발전과 수술 방법의 향상으로 완치를 시도하려는 노력이 지속되고 있으며 현재까지의 연구결과를 종합해 본다면 우선 절제 가능한 대장암 간 전이의 경우에도 수술 전후의 항암화학요법이 추천되며 초기에는 절제가 어려운 간 전이의 경우에도 반응률이 높은 항암화학요법을 시도하여 종양의 크기 감소가 뚜렷하다면 수술적 절제를 고려해야 할 것이다. 하지만 수술 전 항암제 투여 기간 등은 수술 후 합병증이나 간 손상 등과의 연관성에 대해 고려해야 하겠고, 처음 항암 제치료를 결정할 때 특히 cetuximab의 사용을 계획한다면 KRAS 돌연변이와 같은 종양의 생물학적 예측인자에 대한고려가 있어야 한다. 간 전이를 포함한 종양의 완전 절제 후 에도 재발율을 줄이기 위한 수술 후 보조

Abstract Abstract 5141 Incorporation of bortezomib in the treatment of multiple myeloma (MM) has significantly imporved patient outcome. Because peripheral neuropathy (PN) leading to dose modification and drug discontinuation seems to be dependent on dose and exposure of bortezomib, some schedules of botezomib therapy were reduced from twice-weekly to once-weekly infusion. We assessed the efficacy and safety of once-weekly bortezomib infusion in the treatment of relapsed/refractory MM. We compar